Benitec Biopharma (BNTC) Stock Statistics & Valuation Metrics

Benitec Biopharma has a market cap or net worth of $365.37M. The enterprise value is $488.77M.

Benitec Biopharma has 33,862,225 shares outstanding. The number of shares has decreased by -2.65% in one year.

Benitec Biopharma’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -42.55%.

The current PE Ratio of Benitec Biopharma is ―. Benitec Biopharma’s PEG ratio is 0.18.

In the last 12 months, Benitec Biopharma had revenue of 0.00 and earned -37.92M in profits. Earnings per share was -1.05.

In the last 12 months, operating cash flow was -22.67M and capital expenditures -18.00K, giving a free cash flow of -22.69M billion.

Benitec Biopharma pays an annual dividend of $0.765, resulting in a dividend yield of ―

Benitec Biopharma upcoming earnings date is Feb 16, 2026, After Close (Confirmed).

Benitec Biopharma as a current ratio of 54.67, with Debt / Equity ratio of 0.87%

In the past 12 months, Benitec Biopharma has paid 0.00 in taxes.

Benitec Biopharma EV to EBITDA ratio is -7.84, with an EV/FCF ratio of -13.84.

Benitec Biopharma has $94.48M in cash and marketable securities with $817.00K in debt, giving a net cash position of $93.66M billion.

Gross margin is 16.37%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Benitec Biopharma is $26.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy